Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | HEL 92.1.7 is a human erythroleukemia cell line derived from the peripheral blood of a 30-year-old male patient with erythroleukemia. The cells exhibit a lymphoblast-like or proerythroblast-like morphology and grow in suspension culture either as single cells or in loose clusters. A notable genetic feature of HEL 92.1.7 is the presence of a homozygous JAK2 V617F mutation, making it a classic model for studying the JAK/STAT signaling pathway. Furthermore, this cell line possesses multipotent hematopoietic differentiation potential; upon treatment with specific chemical inducers, HEL 92.1.7 cells can be prompted to synthesize hemoglobin or express megakaryocytic markers. Given its well-defined genomic background and unique hematopoietic phenotype, HEL 92.1.7 is widely used to investigate erythroid and megakaryocytic differentiation pathways, explore the pathogenesis of myeloproliferative neoplasms (MPNs), evaluate JAK2-targeted inhibitors, and conduct high-throughput drug screening. |
| Tissue | Peripheral blood / Bone marrow |
| Disease | Erythroleukemia; Acute Myeloid Leukemia (AML); Myeloproliferative Neoplasm (MPN) |
| Morphology | Lymphoblast-like / Erythroblast-like |
| Gender | Male |
| Age | 30 years |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Research on myeloproliferative neoplasms (MPN) and the constitutive activation of JAK2 V617F kinase; 2. Evaluation and screening of selective JAK2 inhibitors and small-molecule targeted therapeutic agents; 3. In vitro models for studying erythroid and megakaryocytic lineage differentiation and globin gene expression; 4. Functional genomic analysis, target validation, and validation studies based on CRISPR/Cas9 screening. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Karyotype | Triploid / Aneuploid |
| Tumorigenic | Yes, forms tumors in immunocompromised mice |
| Genetic Profile | JAK2 V617F homozygous mutation; TP53 mutation; NRAS wild-type |
| Expression Markers | Expresses erythroid markers (Glycophorin A/CD235a) and megakaryocytic markers (CD41, CD61); secretes hemoglobin upon induction |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Maintain the cultures by adding fresh medium or replacing the existing medium. 2. Establish the culture system by centrifuging the cells (1,000 rpm, 5 minutes) and resuspending them to achieve a viable cell density of 1 × 10⁵ to 3 × 10⁵ cells/mL. 3. The cell concentration must not exceed 1.5 × 10⁶ cells/mL. 4. Before subculturing (transferring to a new vessel), gently resuspend the cells to prepare a single-cell suspension. |
| Medium Renewal | Every 2 to 3 days |
| Subcultivation Ratio | Maintain cell density between 1 × 10⁵ and 1.5 × 10⁶ cells/mL (split ratio approximately 1:3 to 1:6) |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% to 10% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0571M | Luciferase Reporter Cell Line - HEL92.1.7 | Inquiry |
| CSC-RO01596 | OVAL Stable Cell Line - HEL92.1.7 | Inquiry |
| CSC-RO01849 | GFP/OVAL Stable Cell Line - HEL92.1.7 | Inquiry |
| CSC-RO02102 | Luc/OVAL Stable Cell Line - HEL92.1.7 | Inquiry |
| CSC-RO02355 | GFP/Luc/OVAL Stable Cell Line - HEL92.1.7 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.